<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567422</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2015-01643</org_study_id>
    <secondary_id>NCI-2015-01643</secondary_id>
    <secondary_id>9950</secondary_id>
    <secondary_id>9950</secondary_id>
    <secondary_id>N01CM00100</secondary_id>
    <secondary_id>UM1CA186690</secondary_id>
    <secondary_id>UM1CA186691</secondary_id>
    <nct_id>NCT02567422</nct_id>
  </id_info>
  <brief_title>Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer</brief_title>
  <official_title>A Phase I Study of M6620 (VX-970, Berzosertib) in Combination With Cisplatin and XRT in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of berzosertib (M6620) when given&#xD;
      together with cisplatin and radiation therapy in treating patients with head and neck&#xD;
      squamous cell carcinoma that has spread from where it started to nearby tissue or lymph nodes&#xD;
      (locally advanced). M6620 may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Chemotherapy drugs, such as cisplatin, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by&#xD;
      stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells&#xD;
      and shrink tumors. Giving M6620 together with cisplatin and radiation therapy may work better&#xD;
      in treating patients with locally advanced head and neck squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the safety and tolerability of M6620 (VX-970, berzosertib) when administered along&#xD;
      with weekly cisplatin and radiation therapy (XRT) in patients with locoregionally advanced&#xD;
      head and neck squamous cell carcinoma (HNSCC).&#xD;
&#xD;
      II. Establish the recommended phase 2 dose (RP2D) of the combination.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Characterize the pharmacokinetic (PK) profile of M6620 (VX-970, berzosertib).&#xD;
&#xD;
      II. Assess for potential drug-drug interaction between M6620 (VX-970, berzosertib) and&#xD;
      aprepitant.&#xD;
&#xD;
      III. To observe and record anti-tumor activity. IV. To assess the rate of complete metabolic&#xD;
      response (CMR) at 12 weeks post completion of chemoradiation using 18 fluorodeoxyglucose&#xD;
      (FDG) positron emission tomography (PET) scans.&#xD;
&#xD;
      V. To collect archival tumor material for retrospective analysis of association between&#xD;
      tissue-based biomarkers and clinical outcome.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of berzosertib.&#xD;
&#xD;
      Patients receive berzosertib intravenously (IV) over 60 minutes on day -7 and then weekly on&#xD;
      day 2 and cisplatin IV over 30-60 minutes weekly on day 1. Patients also undergo radiation&#xD;
      therapy once daily, 5 days a week. Treatment continues for up to 7 weeks in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days, every 2 weeks for&#xD;
      3 months, and then every 3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2016</start_date>
  <completion_date type="Anticipated">September 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 12, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and grade of toxicity</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>According to the Cancer Therapy Evaluation Program National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v. 5).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities</measure>
    <time_frame>Up to completion of radiation therapy</time_frame>
    <description>Graded according to NCI CTCAE v. 5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase 2 dose</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>Defined as the highest doses of cisplatin and berzosertib safely combined with radiation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic characteristics of berzosertib</measure>
    <time_frame>At baseline, 30 and 55 minutes after start of infusion, 5, 15, and 30 minutes and 1, 2, 4, 23, 48, and 72 hours after end of infusion</time_frame>
    <description>Calculating maximum concentration, area under the curve, clearance, half-life, and steady state volume using Wilcoxon (non-parametric) test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate defined as complete response (CR) + partial response (PR)</measure>
    <time_frame>From the time measurement criteria are met for CR or PR until the first date that recurrent or progressive disease is objectively documented, assessed up to 2 years</time_frame>
    <description>Evaluated by Response Evaluation Criteria in Solid Tumors 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic response rate by fluorodeoxyglucose-positron emission tomography (PET)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Measured by PET Response Criteria in Solid Tumors.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Expression of tissue-based biomarkers as markers of deoxyribonucleic acid damage and predictors of clinical outcome</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Head and Neck Carcinoma of Unknown Primary</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7</condition>
  <condition>Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7</condition>
  <condition>Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7</condition>
  <condition>Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IV Sinonasal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7</condition>
  <condition>Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7</condition>
  <condition>Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7</condition>
  <condition>Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7</condition>
  <arm_group>
    <arm_group_label>Treatment (berzosertib, cisplatin, radiation therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive berzosertib IV over 60 minutes on day -7 and then weekly on day 2 and cisplatin IV over 30-60 minutes weekly on day 1. Patients also undergo radiation therapy once daily, 5 days a week. Treatment continues for up to 7 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berzosertib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (berzosertib, cisplatin, radiation therapy)</arm_group_label>
    <other_name>2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-</other_name>
    <other_name>M 6620</other_name>
    <other_name>M6620</other_name>
    <other_name>VX 970</other_name>
    <other_name>VX-970</other_name>
    <other_name>VX970</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (berzosertib, cisplatin, radiation therapy)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (berzosertib, cisplatin, radiation therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Treatment (berzosertib, cisplatin, radiation therapy)</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>ENERGY_TYPE</other_name>
    <other_name>Irradiate</other_name>
    <other_name>Irradiated</other_name>
    <other_name>Irradiation</other_name>
    <other_name>Radiation</other_name>
    <other_name>Radiation Therapy, NOS</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>Radiotherapy</other_name>
    <other_name>RT</other_name>
    <other_name>Therapy, Radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed head and neck squamous&#xD;
             cell cancer (HNSCC) including paranasal sinus cancers but excluding nasopharyngeal&#xD;
             carcinomas&#xD;
&#xD;
          -  Clinical staged III or IV HNSCC that is not amenable to surgical resection&#xD;
&#xD;
          -  Carcinoma of the neck of unknown primary site origin (regardless of HPV/p16 status) is&#xD;
             eligible&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)&#xD;
&#xD;
          -  Life expectancy of greater than 3 months&#xD;
&#xD;
          -  Patients must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded for&#xD;
             non-nodal lesions and short axis for nodal lesions) as &gt;= 20 mm (&gt;= 2 cm) with&#xD;
             conventional techniques or as &gt;= 10 mm (&gt;= 1 cm) with spiral computed tomography (CT)&#xD;
             scan, magnetic resonance imaging (MRI), or calipers by clinical exam&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mcL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Total bilirubin within normal institutional limits&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x institutional upper limit of normal&#xD;
&#xD;
          -  Creatinine within normal institutional limits OR creatinine clearance &gt;= 60&#xD;
             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal&#xD;
&#xD;
          -  The effects of M6620 (VX-970, berzosertib) on the developing human fetus are unknown;&#xD;
             for this reason and because DNA-damage response (DDR) inhibitors as well as other&#xD;
             therapeutic agents used in this trial may have teratogenic potential, women of&#xD;
             child-bearing potential and men must agree to use adequate contraception (hormonal or&#xD;
             barrier method of birth control; abstinence) prior to study entry and for the duration&#xD;
             of study participation; should a woman become pregnant or suspect she is pregnant&#xD;
             while she or her partner is participating in this study, she should inform her&#xD;
             treating physician immediately; men treated or enrolled on this protocol must also&#xD;
             agree to use adequate contraception prior to the study, for the duration of study&#xD;
             participation, and for 6 months after completion of M6620 (VX-970, berzosertib)&#xD;
             administration&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Women of childbearing potential who are sexually active should be willing and able to&#xD;
             use medically acceptable forms of contraception throughout the treatment phase of the&#xD;
             trial and for up to 6 months following the last administration of study treatment; men&#xD;
             who are sexually active must be willing and able to use medically acceptable forms of&#xD;
             contraception throughout the treatment phase of the trial and for 6 months after&#xD;
             completion of M6620 (VX-970, berzosertib) administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with nasopharyngeal carcinoma, skin squamous cell carcinoma (SCC), and&#xD;
             salivary gland carcinomas are not eligible&#xD;
&#xD;
          -  Patients who are receiving adjuvant chemoradiation after surgical resection of the&#xD;
             primary site of disease&#xD;
&#xD;
          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for&#xD;
             nitrosoureas or mitomycin C) prior to entering the study or those who have not&#xD;
             recovered from adverse events due to agents administered more than 4 weeks earlier&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents&#xD;
&#xD;
          -  Patients on tacrolimus or any other immunosuppressants with significant interaction&#xD;
             with cisplatin&#xD;
&#xD;
          -  Patient who requires live vaccine administration&#xD;
&#xD;
          -  Patients with known brain metastases should be excluded from this clinical trial&#xD;
             because of their poor prognosis and because they often develop progressive neurologic&#xD;
             dysfunction that would confound the evaluation of neurologic and other adverse events&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to M6620 (VX-970, berzosertib) or cisplatin&#xD;
&#xD;
          -  Prior systemic chemotherapy for the current cancer (prior chemotherapy for a different&#xD;
             cancer is allowed)&#xD;
&#xD;
          -  Prior receipt of radiotherapy that would result in overlap of the new and old&#xD;
             radiation therapy fields&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to:&#xD;
&#xD;
               -  Ongoing or active infection requiring intravenous antibiotics at the time of&#xD;
                  treatment initiation&#xD;
&#xD;
               -  Symptomatic congestive heart failure (requiring hospital stay within the last 6&#xD;
                  months)&#xD;
&#xD;
               -  Myocardial infarction within the last 6 months&#xD;
&#xD;
               -  Unstable angina pectoris, cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness/social situations that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study because M6620 (VX-970, berzosertib) as a&#xD;
             DNA-damage response (DDR) inhibitor may have the potential for teratogenic or&#xD;
             abortifacient effects; because there is an unknown but potential risk for adverse&#xD;
             events in nursing infants secondary to treatment of the mother with M6620 (VX-970,&#xD;
             berzosertib), breastfeeding should be discontinued if the mother is treated with M6620&#xD;
             (VX-970, berzosertib); these potential risks may also apply to other agents used in&#xD;
             this study&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as&#xD;
             determined by CD4 count and viral load, who are on antiretroviral therapy that does&#xD;
             not contain a strong inducer or inhibitor of CYP3A4 are allowed on trial; HIV-positive&#xD;
             patients on combination antiretroviral therapy with strong inducers or inhibitors of&#xD;
             CYP3A4 are ineligible because of the potential for pharmacokinetic interactions;&#xD;
             patients with poorly controlled HIV are not eligible due to the increased risk of&#xD;
             lethal infections when treated with marrow-suppressive therapy&#xD;
&#xD;
          -  Definitive clinical or radiographic evidence of distant metastasis or adenopathy below&#xD;
             the clavicles&#xD;
&#xD;
          -  M6620 (VX-970, berzosertib) is primarily metabolized by CYP3A4; therefore, concomitant&#xD;
             administration with strong inhibitors or inducers of CYP3A4 should be avoided; because&#xD;
             the lists of these agents are constantly changing, it is important to regularly&#xD;
             consult a frequently-updated medical reference for a list of drugs to avoid or&#xD;
             minimize use of; as part of the enrollment/informed consent procedures, the patient&#xD;
             will be counseled on the risk of interactions with other agents, and what to do if new&#xD;
             medications need to be prescribed or if the patient is considering a new&#xD;
             over-the-counter medicine or herbal product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taofeek K Owonikoko</last_name>
    <role>Principal Investigator</role>
    <affiliation>JHU Sidney Kimmel Comprehensive Cancer Center LAO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>916-734-3089</phone>
    </contact>
    <investigator>
      <last_name>Jonathan W. Riess</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Center/Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>203-785-5702</phone>
      <email>canceranswers@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara A. Burtness</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>203-785-5702</phone>
      <email>canceranswers@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara A. Burtness</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital Care Center-Trumbull</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>203-785-5702</phone>
      <email>canceranswers@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara A. Burtness</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>888-946-7447</phone>
    </contact>
    <investigator>
      <last_name>Conor E. Steuer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>404-778-1868</phone>
    </contact>
    <investigator>
      <last_name>Conor E. Steuer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>859-257-3379</phone>
    </contact>
    <investigator>
      <last_name>Susanne M. Arnold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-888-8823</phone>
    </contact>
    <investigator>
      <last_name>Ranee Mehra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>313-576-9790</phone>
      <email>ctoadmin@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Ammar Sukari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-639-6918</phone>
      <email>cancer.research.nurse@dartmouth.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas H. Davis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-293-5066</phone>
      <email>Jamesline@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Darrion L. Mitchell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>412-647-8073</phone>
    </contact>
    <investigator>
      <last_name>Dan P. Zandberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>434-243-6303</phone>
      <email>uvacancertrials@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Varinder Kaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-622-8922</phone>
    </contact>
    <investigator>
      <last_name>Justine Yang-Bruce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 2, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

